100 Clinical Results associated with Shield Biotech, Inc.
0 Patents (Medical) associated with Shield Biotech, Inc.
01 Nov 2015·ImmunotherapyQ4 · MEDICINE
Immunotherapy for Breast Cancer: Is it Feasible?
Q4 · MEDICINE
Highlights
Author: Stanton, Sasha E ; Emens, Leisha A ; Tuohy, Vincent K
Immunotherapy invited leading experts in the field to share their thoughts on two key immunotherapeutic strategies in the field of breast cancer research, vaccines and checkpoint inhibitors. Interviewed by Ellen Clarke (Commissioning Editor, Future Science Group). Historically breast cancer has been considered immunologically silent. Patients have had limited access to the types of immunotherapy available to melanoma and lung cancer patients, but this could all be set to change as recent preclinical and clinical studies have highlighted the potential of immunotherapy for breast cancer. Breast cancer is now one of the major cancer types for which new immune-based treatments are being developed.
01 Oct 2014·Cleveland Clinic Journal of MedicineQ4 · MEDICINE
Bench-to-bedside challenges in developing immune protection against breast cancer
Q4 · MEDICINE
Article
Author: Tuohy, Vincent K
Despite the success of childhood vaccination against infectious diseases, vaccines are lacking against diseases that occur with age. We are developing a vaccine to prevent breast cancer. This article explains the vaccine strategy, how we think the vaccine will work, and how we plan to move forward through clinical trials.
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
Q2 · MEDICINE
ArticleOA
Author: Loya, Matthew G ; Downs-Kelly, Erinn ; Jaini, Ritika ; Johnson, Justin M ; Wilk, Dennis ; Tuohy, Vincent K ; Mazumder, Suparna
We have proposed that safe and effective protection against the development of adult onset cancers may be achieved by vaccination against tissue-specific self-proteins that are “retired” from expression at immunogenic levels in normal tissues as we age, but are overexpressed in emerging tumors. α-Lactalbumin is an example of a “retired” self-protein because its expression in normal tissues is confined exclusively to the breast during late pregnancy and lactation, but is also expressed in the vast majority of human triple negative breast cancers (TNBC)—the most aggressive and lethal form of breast cancer and the predominant form that occurs in women at high genetic risk including those with mutated BRCA1 genes. In anticipation of upcoming clinical trials, here we provide preclinical data indicating that α-lactalbumin has the potential as a vaccine target for inducing safe and effective primary immunoprevention as well as immunotherapy against TNBC.
100 Deals associated with Shield Biotech, Inc.
100 Translational Medicine associated with Shield Biotech, Inc.
